The review says incretin drugs can reduce sleep apnea severity in adults with obesity, alongside weight loss and some heart and metabolic gains.
Recap by typeshit. Full story at News-Medical.Net.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
Robert Lufkin MD shares the observational data: an average 16.1 kg lost at six months among 7,297 women, with 62.7% reporting side effects.
An international food and agribusiness expert links growing interest in fibre to the spread of GLP-1 drugs. Details are thin beyond the claim itself.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Loading…